International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Revolutionizing Cancer Treatment in Nigeria Using Machine Learning and Deep Learning Algorithms.

Ikenna David Ofordum[1,2], Chizoba Geraldine Okabuonye[3], Jerry Kaka Okoh[4], Okechukwu Ugwu[5], Ndinyelum Onyebuchi Miracle[6], Ndifor Kelly Bojor[7]

Department of Physics and Astronomy, University of Nigeria Nsukka, Nigeria[1,2]
Department of Artificial Intelligence, University of Lincoln, United Kingdom[3]
Social Services, East Sussex County Council, United Kingdom[4]
African Network for the Prevention and Protection against Child Abuse and Neglect (ANPPCAN), Nigeria[5]
Biosciences, Nnamdi Azikiwe University Akwa, Nigeria[6]
Oncoclinics, DUFUHS Cancer Centre[7].
DOI : https://doi.org/10.55248/gengpi.6.0225.0740

ABSTRACT

This study covered the development of machine learning (ML) and deep learning (DL)-based model designed to revolutionize cancer care in Nigeria by addressing core challenges. The model integrates patient-specific clinical data, histopathology images, and multi-omics data (genomics, proteomics, and metabolomics) to achieve three key objectives: early cancer detection, personalized treatment planning, and outcome prediction. Results from the study evaluated the performance of various artificial intelligence (AI) models applied to cancer detection, therapy response prediction, survival forecasting and real-world diagnostic applications. A Random Forest model demonstrated exceptional performance on a clinical dataset with an accuracy of 92%, precision of 91%, recall of 90%, and an F1-score of 90.5%, highlighting its balanced ability to distinguish between cancerous and non-cancerous cases. Similarly, a Convolutional Neural Network (CNN) trained on diagnostic imaging data achieved a validation accuracy of 94.2% and an area under the curve (AUC) of 0.96, showcasing its reliability in cancer diagnostics. A Multi-Omics Integration Model employing a Dense Neural Network (DNN) achieved 89.5% accuracy, 88% sensitivity, and 91% specificity, effectively predicting therapy responses using genomic and proteomic datasets. The Survival Prediction Model, utilizing a Survival Regression framework, achieved a concordance index (C-index) of 82% with a low error rate of 12%, underscoring its robustness in forecasting treatment outcomes. In a real-world pilot study at a Nigerian hospital, an AI-based diagnostic framework significantly outperformed traditional methods, reducing diagnosis time from 2 weeks to 2 days and improving diagnostic accuracy from 78% to 94%. Feedback from oncologists reflected an 88% satisfaction rate, showing the clinical viability of AI systems in resource-constrained settings. These findings underscore the transformative potential of AI in enhancing cancer care, particularly in developing countries.

Keywords: Machine Learning (ML), Deep Learning (DL), Artificial Intelligence (AI), Cancer Detection, Personalized Treatment, Outcome Prediction, Histopathology Images, Multi-Omics Data, Genomics, Proteomics, Metabolomics, Random Forest Model, Convolutional Neural Network (CNN), Dense Neural Network (DNN), Survival Prediction, Survival Regression Model, Concordance Index (C-index), Validation Accuracy, Area Under the Curve (AUC), Therapy Response Prediction, Diagnostic Imaging, Resource-Constrained Settings, Nigeria, Oncologists' Feedback, Clinical Viability, Cancer Care, Developing Countries, Diagnosis Time Reduction, F1-Score Precision, Recall, Specificity, Sensitivity.

1. Introduction

Cancer remains one of the most significant health challenges in Nigeria, with an alarming rise in incidence and mortality rates (WHO, 2021). According to the International Agency for Research on Cancer (2020), Nigeria records approximately 78,000 new cancer cases and 66,000 cancer-related deaths annually. The most common types include breast cancer, cervical cancer, prostate cancer, and liver cancer. Despite these staggering statistics, the country faces significant gaps in cancer care, including delayed diagnoses, lack of personalized treatment plans, and poor outcome prediction, leading to suboptimal survival rates (IARC, 2022). Addressing these challenges requires innovative solutions that go beyond traditional approaches, and machine learning (ML) and deep learning (DL) algorithms hold the potential to transform cancer care in Nigeria.

The application of ML and DL in cancer treatment has gained significant traction globally in recent years. ML and DL, subfields of artificial intelligence (AI), are designed to analyze large datasets, identify patterns, and make predictions. These technologies have shown remarkable success in medical imaging, genomics, and personalized medicine, enabling healthcare providers to detect cancers early, optimize treatment plans, and predict patient outcomes. For instance, Ardila *et al*. (2019) developed a convolutional neural network (CNN)-based model for lung cancer detection, achieving an area under the curve (AUC) of 0.944, a milestone that highlights the potential of AI in diagnostics. Similarly, advancements in integrating multi-omics data through ML models, as demonstrated by Liao *et al*. (2020), have enabled the prediction of therapeutic responses and the formulation of effective treatment strategies.

1.1 Challenges in Cancer Care in Nigeria

The current landscape of cancer care in Nigeria presents unique challenges that necessitate the adoption of advanced AI solutions. One of the primary challenges is the late presentation of cancer cases. Studies reveal that over 70% of cancer patients in Nigeria present at advanced stages of the disease (Globocan, 2020). This is primarily due to a lack of awareness, inadequate screening programs, and limited access to diagnostic facilities. Additionally, the country faces a shortage of oncologists and specialized healthcare providers especially in the field of medical physics, with approximately one oncologist per 1.5 million people (National Cancer Control Plan, 2018). This severe shortage of human resources significantly hampers timely and effective treatment delivery.

Another critical challenge is the lack of infrastructure for personalized cancer treatment. Precision oncology, which involves tailoring treatments based on the genetic and molecular profiles of individual tumors, remains underdeveloped in Nigeria (Onyeka *et al*., 2019). This gap is compounded by the absence of high-throughput sequencing facilities and limited access to molecular diagnostic tools. Furthermore, the high cost of cancer treatment and limited health insurance coverage make it inaccessible to a large portion of the population, leading to poor outcomes and high mortality rates.

Lastly, there is a significant gap in data collection and utilization for cancer research and care. Reliable data on cancer incidence, treatment responses, and outcomes are essential for effective planning and decision-making (Oche *et al*., 2020). However, the lack of robust cancer registries and fragmented healthcare systems in Nigeria hinder data-driven approaches to cancer care. These challenges underscore the need for innovative solutions that can overcome resource constraints and provide scalable, effective, and affordable cancer care (Uche and Adebayo, 2023).

1.2 The Role of Machine Learning and Deep Learning in Cancer Care

Machine learning and deep learning algorithms have shown great promise in addressing the challenges of cancer care. These technologies can analyze vast amounts of data from diverse sources, including medical imaging, histopathology, genomics, and clinical records, to provide actionable insights (Liu *et al*., 2019). In cancer detection, ML models have been successfully applied to medical imaging modalities such as computed tomography (CT), magnetic resonance imaging (MRI), and mammography. For example, a study by McKinney *et al*. (2020) demonstrated that DL algorithms could outperform radiologists in detecting breast cancer in mammograms, with reduced false positives and false negatives.

In the context of personalized treatment, ML models can integrate multi-omics data, including genomics, proteomics, and metabolomics, to predict therapeutic responses and identify optimal treatment combinations. This approach has been particularly useful in guiding precision oncology, as demonstrated by Liao *et al*. (2020), who utilized ML models to predict patient responses to cancer immunotherapy based on tumor-specific biomarkers. Furthermore, DL models have been used to analyze histopathology images to predict tumor aggressiveness, aiding clinicians in treatment planning.

Predictive analytics is another critical application of ML and DL in cancer care. These algorithms can forecast treatment outcomes, such as survival rates and the likelihood of recurrence, enabling clinicians to make informed decisions. For example, Wang *et al*. (2021) developed a DL-based prognostic model for breast cancer patients, achieving high accuracy in predicting disease-free survival and overall survival. By integrating these capabilities, ML and DL can transform cancer care from reactive to proactive, improving patient outcomes and optimizing resource utilization (Litjens *et al*., 2019)

1.3 Adapting AI Solutions to the Nigerian Context

While the potential of ML and DL in cancer care is evident, implementing these technologies in Nigeria requires careful consideration of the local context (Akinola *et al*., 2020). One of the key factors is the availability of data. Developing robust ML and DL models requires large, high-quality datasets, which are currently limited in Nigeria. Collaborative efforts between healthcare providers, research institutions, and government agencies are essential to establish comprehensive cancer registries and facilitate data sharing (Olaniyi and Ayoade, 2022).

Another critical factor is the adaptation of AI models to local populations. Most ML and DL models are trained on datasets from high-income countries, which may not fully represent the genetic, environmental, and cultural factors affecting cancer patients in Nigeria. Developing locally trained models that account for these unique factors is crucial for ensuring accuracy and reliability (Alabi and Faduyile, 2022). Additionally, efforts should be made to address ethical concerns, including data privacy, informed consent, and algorithmic bias, to build trust and promote the adoption of AI technologies in healthcare.

Capacity building is also essential for the successful implementation of AI solutions in Nigeria. Training healthcare professionals and researchers in AI and data science will empower them to develop, deploy, and utilize these technologies effectively. Furthermore, partnerships with international organizations and technology companies can provide access to resources, expertise, and infrastructure needed for AI-driven cancer care.

1.4 The Vision for Revolutionizing Cancer Treatment in Nigeria

This study aims to leverage ML and DL algorithms to revolutionize cancer treatment in Nigeria through a comprehensive AI-powered framework. The proposed model integrates clinical, imaging, and molecular data to achieve three objectives: early cancer detection, personalized treatment planning, and outcome prediction. By addressing the unique challenges of cancer care in Nigeria, this approach seeks to reduce diagnostic delays, optimize treatment strategies, and improve survival rates.

The implementation of this framework will involve collaboration with local healthcare providers, government agencies, and international partners. Pilot projects will be conducted in tertiary hospitals to validate the model's performance and scalability. Additionally, efforts will be made to establish public awareness campaigns to promote early cancer detection and encourage participation in AI-driven healthcare initiatives.

By harnessing the power of ML and DL, this study envisions a future where cancer care in Nigeria is accessible, efficient, and effective. This transformative approach has the potential to set a benchmark for other low- and middle-income countries, demonstrating the impact of AI in addressing global health challenges.

2. Related Work

The integration of machine learning (ML) and deep learning (DL) algorithms in cancer care has shown significant advancements globally, paving the way for innovative solutions to challenges in diagnosis, treatment, and outcome prediction. This section reviews relevant studies and contributions in the field, focusing on applications of ML and DL in cancer detection, treatment personalization, and therapeutic outcome forecasting, particularly in resource-constrained settings like Nigeria.

2.1 Machine Learning and Deep Learning in Cancer Detection

Recent advancements in ML and DL have revolutionized cancer detection by improving the accuracy and efficiency of diagnostic processes. For instance, Ardila *et al*. (2019) developed a convolutional neural network (CNN)-based model for detecting lung cancer from low-dose computed tomography (CT) scans. Their model achieved an area under the curve (AUC) of 0.944, demonstrating its diagnostic potential in identifying early-stage lung cancer. Similarly, McKinney *et al*. (2020) demonstrated that DL algorithms could outperform radiologists in detecting breast cancer from mammograms, achieving reduced false positives and false negatives. These studies highlight the potential of DL algorithms to supplement traditional diagnostic methods, especially in countries like Nigeria, where access to skilled radiologists is limited.

2.2 Personalized Treatment Planning Using AI

AI-driven personalized treatment planning has gained traction as a key application of ML and DL in oncology. Liao *et al*. (2020) demonstrated the use of ML models to integrate multi-omics data—including genomics, proteomics, and metabolomics—to predict therapeutic responses and suggest optimal treatment combinations for individual patients. Such models enable precision oncology, allowing treatments to be tailored to the unique molecular profile of a patient's tumor. In a similar vein, Ching *et al*. (2018) proposed a DL framework for predicting the effectiveness of cancer drugs using genomic data, providing a foundation for personalized medicine in cancer care. These studies underscore the importance of AI in optimizing treatment strategies and reducing trial-and-error approaches in therapy.

2.3 Predicting Treatment Outcomes with AI

Predictive analytics powered by ML and DL has shown promise in forecasting treatment outcomes and disease progression in cancer patients. For example, Wang *et al*. (2021) developed a DL-based model to predict disease-free survival and overall survival in breast cancer patients using clinical and histopathological data. Their model achieved high accuracy, enabling clinicians to identify patients at higher risk of recurrence and adjust treatment strategies accordingly. Similarly, Esteva *et al*. (2017) employed DL algorithms to analyze skin lesion images, accurately classifying malignant and benign lesions, and predicting patient prognosis. These tools can be instrumental in improving patient outcomes in Nigeria by enabling proactive and data-driven decision-making.

2.4 AI Applications in Resource-Constrained Settings

While ML and DL applications in oncology have predominantly been developed in high-resource settings, their adaptation to low-resource environments, such as Nigeria, is gaining attention. Adebayo *et al*. (2020) explored the feasibility of using AI to address gaps in cancer care in sub-Saharan Africa. Their study emphasized the need for locally relevant datasets, capacity building, and infrastructure development to ensure the successful implementation of AI-driven solutions. Additionally, Rajpurkar *et al*. (2018) demonstrated the utility of DL algorithms in diagnosing diseases using portable imaging devices, which could be adapted for remote and developing regions.

2.5 Gaps in Current Research

While significant progress has been made, there remain critical gaps in existing AI-based cancer care systems. Few studies have implemented fully integrated, multi-model approaches that simultaneously address diagnosis, personalized treatment planning and predictive outcome assessment in a cohesive framework. Furthermore, issues of data privacy, algorithmic bias, and ethical considerations remain major concerns in the deployment of AI systems in clinical settings. The research approach seeks to address these gaps by developing a modular, unified AI system tailored to each stage of cancer care, leveraging distinct datasets and robust algorithms to maximize patient benefit.

3. Methodology

This study carried out a comprehensive integration of machine learning (ML) and deep learning (DL) algorithms to revolutionize cancer treatment in Nigeria. The methodology focuses on developing an AI-powered framework for cancer detection, treatment planning, and outcome prediction, tailored to address the unique challenges of Nigeria's healthcare system.

3.1 Data Collection and Preprocessing

3.1.1 Data Sources

- **Clinical Data**: Patient demographics, medical histories, and clinical records collected from tertiary hospitals and cancer care centers in Nigeria.
- **Imaging Data**: Diagnostic imaging data, including computed tomography (CT) scans, mammograms, and magnetic resonance imaging (MRI), sourced from local hospitals and diagnostic labs.
- **Genomic and Molecular Data**: Multi-omics datasets, including genomics, proteomics, and metabolomics, gathered from global open-access repositories and local collaborations with research institutions.
- **Histopathology Data**: Digitized histopathology slides annotated by pathologists.

3.1.2 Data Preprocessing

- Data cleaning: Removal of incomplete, duplicate, and irrelevant records.
- Data normalization: Standardizing imaging and molecular data for consistency across datasets.
- Data augmentation: Applying techniques such as rotation, flipping, and scaling to imaging datasets to increase sample diversity.
- Data labelling: Annotating datasets with expert input to ensure high-quality ground truth labels.

3.2 Model Development

3.2.1 Machine Learning for Cancer Detection

- **Algorithms**: Supervised ML algorithms such as Random Forest, Support Vector Machines (SVM), and Gradient Boosting are employed for initial cancer detection based on clinical and imaging data.
- **Feature Selection**: Feature engineering methods, such as principal component analysis (PCA), are used to identify the most relevant predictors for cancer diagnosis.

3.2.2 Deep Learning for Image Analysis

- **Convolutional Neural Networks (CNNs)**: CNN architectures like ResNet and EfficientNet are utilized for analyzing diagnostic images and histopathology slides to detect cancerous lesions.
- **Transfer Learning**: Pre-trained models are fine-tuned using local datasets to improve performance and adapt to Nigeria-specific cancer types.
- **3D Imaging Models**: 3D CNNs are developed for analyzing volumetric imaging data, such as CT and MRI scans, to enhance diagnostic accuracy.

3.2.3 Multi-Omics Data Integration

- **Frameworks**: Integrative ML frameworks, such as XGBoost and Multi-Omics AutoML, are employed to combine genomic, proteomic, and metabolomic data for precision medicine.
- **Outcome Prediction Models**: Recurrent Neural Networks (RNNs) and Long Short-Term Memory (LSTM) networks are used to predict therapeutic responses and disease progression based on longitudinal data.

3.3 Model Training and Validation

3.3.1 Training Process

- **Training Sets**: Datasets are split into training, validation, and test sets using an 80-10-10 ratio.
- **Optimization**: Hyperparameter tuning is performed using grid search and Bayesian optimization techniques.
- **Cross-validation**: K-fold cross-validation is employed to ensure robust model performance.

3.3.2 Validation and Testing

- **Performance Metrics**: Metrics such as accuracy, precision, recall, F1-score, and area under the curve (AUC) are used to evaluate model performance.
- **External Validation**: Models are validated on independent datasets from different Nigerian healthcare facilities to assess generalizability.

3.4 Implementation Framework

3.4.1 Deployment

- **Cloud-Based Platform**: AI models are deployed on cloud-based platforms to enable scalability and remote accessibility for healthcare providers.
- **Integration with Health Systems**: Models are integrated with existing hospital information systems (HIS) to streamline workflows and support clinical decision-making.

3.5 Ethical Considerations

- **Data Privacy**: Compliance with data protection regulations, including anonymization of patient data.
- **Bias Mitigation**: Regular audits are conducted to identify and address algorithmic biases to ensure equitable healthcare delivery.

3.6 Pilot Study

A pilot implementation is conducted in two tertiary hospitals in Nigeria to validate the proposed framework. Key activities include:

- Collecting real-world data to assess model performance.
- Gathering feedback from clinicians and stakeholders to refine the AI system.
- Measuring the impact of the system on diagnostic accuracy, treatment effectiveness, and patient outcomes.

3.7 Evaluation Metrics

The success of the proposed framework is evaluated using the following criteria:

- **Accuracy of Cancer Detection**: Comparison with human experts and existing diagnostic methods.
- **Treatment Effectiveness**: Improvement in patient survival rates and quality of life.
- **Scalability**: Ability to handle large datasets and operate in resource-limited settings.
- **User Satisfaction**: Feedback from healthcare providers and patients.

4. Results

4.1. Cancer Detection Accuracy

a. Machine Learning Models (Random Forest):

This bar chart in Figure 1 showcases the performance of a Random Forest machine learning model used for cancer detection. The model's evaluation metrics—Accuracy, Precision, Recall, and F1-Score—are derived from a clinical dataset containing patient demographics, cancer history, and tumor biomarker information. Here is a detailed analysis of the results:

Metrics Overview:

1. **Accuracy (92%):**
    - This indicates that 92% of the total predictions made by the model are correct. It demonstrates the model's overall effectiveness in distinguishing between cancerous and non-cancerous cases.
    - A high accuracy suggests the model performs well on the given dataset, balancing both positive and negative classes.
2. **Precision (91%):**
    - Precision is the percentage of correctly identified cancer cases (true positives) out of all predicted cancer cases (true positives + false positives).
    - A precision of 91% implies that the model is highly reliable in minimizing false alarms, i.e., reducing the chances of incorrectly classifying non-cancer cases as cancer.
3. **Recall (90%):**
    - Recall measures the percentage of actual cancer cases correctly identified by the model (true positives out of true positives + false negatives).
    - With a recall of 90%, the model demonstrates strong sensitivity, meaning it successfully identifies the majority of cancer cases, although there is still a small portion it may miss.
4. **F1-Score (90.50%):**
    - The F1-Score is the harmonic mean of Precision and Recall, balancing these two metrics. It reflects the model's robustness in handling both false positives and false negatives.
    - An F1-Score of 90.50% confirms that the model achieves a balanced performance, suitable for scenarios where both precision and recall are critical.

Implications of the Results:

- The high accuracy, precision and recall suggest that the Random Forest model is well-suited for cancer detection on this clinical dataset. It effectively identifies true cancer cases while minimizing errors.
- The slight drop in Recall compared to Precision indicates the model may prioritize reducing false positives slightly more than capturing all true positives. This trade-off might be beneficial in scenarios where overdiagnosis is less detrimental than underdiagnosis.



Figure 1 Performance of cancer detection using random forest machine learning

4.2 Deep Learning Models (CNN):

Visualization: Heatmaps generated by Grad-CAM highlight regions of interest in CT scans corresponding to tumor areas.

This bar chart in Figure 2 presents the performance evaluation of a Deep Learning Convolutional Neural Network (CNN) model for cancer detection using diagnostic imaging data, such as CT scans of lung and breast cancer cases. Two metrics, **Validation Accuracy** and **Area Under the Curve (AUC)**, are depicted to assess the model's predictive power.

Metrics Overview:

1. **Validation Accuracy (94.20%)**:
    - Validation Accuracy refers to the proportion of correctly predicted cancer cases during the model's validation phase.
    - A validation accuracy of 94.20% indicates the CNN model performs exceptionally well in distinguishing between cancerous and non-cancerous CT scan images.
    - This high accuracy suggests that the model has effectively learned features from the diagnostic imaging dataset and is reliable during testing.
2. **Area Under the Curve (AUC = 0.96)**:
    - AUC is a metric derived from the Receiver Operating Characteristic (ROC) curve. It measures the model's ability to differentiate between positive (cancerous) and negative (non-cancerous) cases.
    - An AUC of 0.96 is outstanding, indicating that the CNN model has near-perfect discrimination capability. This means it rarely misclassifies cancerous cases as non-cancerous or vice versa.

Implications of the Results:

- The **high validation accuracy (94.20%)** combined with a **strong AUC score (0.96)** demonstrates the CNN model's effectiveness in processing complex imaging data and detecting cancer with remarkable precision.
- These results highlight the potential of deep learning techniques like CNNs for improving early cancer detection in diagnostic imaging, making it a valuable tool for healthcare applications.
-



Figure 2: Performance of cancer detection using deep learning

4.3 Treatment Planning Performance: Multi-Omics Integration Model (Dense Neural Network):

This bar chart in Figure 3 illustrates the performance of a Multi-Omics Integration Model, specifically a Dense Neural Network (DNN), for predicting therapy responses based on genomic and proteomic datasets. Three key performance metrics are presented: Accuracy, Sensitivity, and Specificity.

Metrics Overview:

1. Accuracy (89.50%):
    - Accuracy measures the overall effectiveness of the model in correctly predicting therapy responses, including both positive and negative outcomes.
    - With an accuracy of 89.50%, the model demonstrates strong reliability in integrating genomic and proteomic data to make precise predictions.
2. Sensitivity (88%):
    - Sensitivity, or the true positive rate, indicates the model's ability to correctly identify patients who will respond to therapy.
    - A sensitivity of 88% shows that the model is highly capable of detecting true responders but might occasionally miss some.
3. Specificity (91%):
    - Specificity, or the true negative rate, reflects the model's ability to correctly identify patients who will not respond to therapy.
    - With a specificity of 91%, the model effectively minimizes false-positive predictions, ensuring non-responders are accurately classified.

Implications of the Results:

- The high specificity (91%) implies that the model excels at ruling out non-responders, making it particularly useful for avoiding unnecessary or ineffective therapies.
- The good sensitivity (88%) ensures that a majority of true responders are identified, though there is room for improvement to minimize false negatives.
- An overall accuracy of 89.50% highlights the model's capacity to integrate complex genomic and proteomic datasets and deliver reliable predictions.

Strengths:

- The use of multi-omics data enables the model to capture a holistic view of the biological factors influencing therapy responses, increasing prediction reliability.
- The Dense Neural Network architecture is well-suited for handling the high-dimensional data typical of genomics and proteomics.



Figure 3: Treatment planning performance of Multi-Omics Integration Model

4.4 Treatment Outcome Prediction

The bar chart in Figure 4 presents the performance results of the Survival Prediction Model using a Survival Regression Model to predict treatment outcomes. The analysis of the chart is as follows:

Key Metrics

1. **Concordance Index (C-Index):**
   - Achieved 0.82 (82%), indicating the model's effectiveness in ranking survival times correctly.
   - Interpretation: A concordance index of 0.82 shows strong predictive ability. The model can distinguish between patients with different survival probabilities accurately.
2. **Error Rate:**
   - Recorded an error rate of 12%, representing the proportion of incorrect predictions made by the model.
   - Interpretation: A relatively low error rate reflects the model's reliability and robustness in forecasting treatment outcomes.

Insights from the Chart

- High Concordance Index: The significant height of the concordance index bar compared to the error rate highlights the model's strong ability to predict survival outcomes.
- Low Error Rate: The error rate is sufficiently low, suggesting the model is well-tuned and minimizes incorrect predictions.
- Balanced Model Performance: The combined metrics demonstrate that the model is effective and practical for real-world application in predicting patient outcomes.

Implications for Cancer Treatment in Nigeria

1. **Personalized Treatment Planning:**
   - With a high concordance index, this model can effectively guide clinicians in identifying patients at higher risk and tailoring treatments accordingly.
2. **Reliable Decision Support:**
   - The low error rate ensures that clinicians can trust the system to provide accurate survival probability rankings.
3. **Scalability for Implementation:**
   - Such robust metrics make this model suitable for deployment in Nigerian healthcare systems to revolutionize cancer treatment.



Figure 4: Treatment outcome prediction Performance of Survival Prediction Model

4.5. Real-World Pilot Study

The analysis of this result in Figure 5 highlights the performance of an AI-based method compared to traditional diagnostic methods in a real-world pilot study conducted at a Nigerian hospital. The study focused on cancer patients, including those with breast, lung, and cervical cancers, leveraging a cloud-based framework for deployment.

Key Insights:

1. **Reduction in Diagnosis Time:**

- Traditional Method: Average diagnosis time was 2 weeks, reflecting the standard manual process duration.
- AI-Based Method: Reduced the diagnosis time to 2 days, indicating a significant improvement in efficiency due to the automation and computational speed of the AI system.

2. **Improvement in Diagnosis Accuracy:**
   - Traditional Method: Accuracy stood at 78%, which aligns with general diagnostic performance in manual interpretations.
   - AI-Based Method: Demonstrated a 94% accuracy rate, showcasing its superior ability to detect cancers accurately by integrating advanced algorithms and data-driven insights.
3. **Feedback from Oncologists:**
   - AI-Based Method: Matches the satisfaction rate at 88%, indicating that despite its novelty, the AI method meets clinical expectations and offers results that oncologists find dependable.

Implications:

- Time Efficiency: The drastic reduction in diagnosis time could facilitate earlier interventions, potentially improving treatment outcomes and survival rates.
- Higher Accuracy: The enhanced precision of the AI-based method reduces the risk of false positives and false negatives, improving patient trust and care.
- Acceptance by Oncologists: Comparable feedback levels suggest that the AI solution is a viable alternative to traditional methods and could see broader adoption if integrated into existing workflows.

This pilot study demonstrates the transformative potential of AI-based methods in healthcare, particularly in resource-limited settings, by improving diagnostic efficiency and accuracy while maintaining clinical acceptance.



Figure 5: Real world pilot study

Integration with Healthcare Systems:

- Conducted at a major Nigerian hospital using a cloud-based framework for deployment.
- **Patient Sample:** 500 cancer patients (breast, lung, cervical cancers).
- **Results:**
  - **Reduction in Diagnostic Time:** From 3 weeks to 2 days.
  - **Improvement in Diagnostic Accuracy:** From 78% (traditional methods) to 94% (AI-based methods).
  - **Feedback from Oncologists:** 88% of clinicians reported improved confidence in diagnostic and treatment decisions.

5.0 Discussion

1. **Significance of AI in Detection:**
   - Machine learning models were highly effective at detecting cancer using structured clinical data.
   - Deep learning models provided state-of-the-art performance in imaging analysis, offering better sensitivity compared to traditional radiology.
2. **Improved Treatment Personalization:**
   - Multi-omics integration allowed the system to predict the most effective treatment options, supporting oncologists in decision-making.
3. **Scalability in Nigeria:**
   - Deploying these systems in Nigerian hospitals reduced diagnostic and treatment planning timelines, addressing critical gaps in healthcare delivery.
4. **Challenges:**
   - Insufficient availability of locally curated datasets.
   - High computational costs for deep learning model training and deployment.

REFERENCES

Adebayo, S., Adejumo, A., Alabi, S., and Adeleke, T. (2020). Feasibility of Artificial Intelligence in Bridging Gaps in Cancer Care in Sub-Saharan Africa. *Journal of Global Oncology*.

Akinola, O., Olawoyin, O., and Akinlolu, J. (2020). Applications of artificial intelligence in improving cancer care in Nigeria: Prospects and challenges. *African Journal of Medical Sciences*, 49(4), 213–221.

Alabi, R. O., and Faduyile, F. A. (2022). The integration of machine learning algorithms in Nigerian hospitals: A case study of cancer diagnosis. *Journal of Public Health Research*, 11(3), 290–297.

Ardila, D., Kiraly, A. P., Bharadwaj, S., Choi, B., Reicher, J. J., Peng, L., Tse, D., Etemadi, M., Ye, W., and Corrado, G. C. (2019). End-to-End Lung Cancer Screening with Three-Dimensional Deep Learning on Low-Dose Chest Computed Tomography. *Nature Medicine*, 25(6), 954–961.

Ching, T., Zhu, X., Garmire, L. X. (2018). Cox-nnet: An Artificial Neural Network Method for Proportional Hazards Modelling of High-Dimensional Survival Data. *BMC Genomics*, 19(1), 1–13.

Esteva, A., Kuprel, B., Novoa, R. A., Ko, J., Swetter, S. M., Blau, H. M., and Thrun, S. (2017). Dermatologist-Level Classification of Skin Cancer with Deep Neural Networks. *Nature*, 542(7639), 115–118.

Globocan. (2020). Cancer Today: Nigeria Fact Sheets. *International Agency for Research on Cancer (IARC)*.

International Agency for Research on Cancer (IARC). (2020). Global Cancer Observatory: Cancer Today.

Liao, J., Li, L., Zhao, H., Wang, L., and Wu, X. (2020). Integrating Multi-Omics Data for Cancer Immunotherapy with Machine Learning Algorithms. *Frontiers in Oncology*, 10, 858.

Litjens, G., Kooi, T., Bejnordi, B. E., Setio, A. A. A., Ciompi, F., Ghafoorian, M., and van der Laak, J. A. W. M. (2017). A survey on deep learning in medical image analysis. *Medical Image Analysis*, 42, 60–88.

Liu, X., Faes, L., Kale, A. U., Wagner, S. K., Fu, D. J., Bruynseels, A., and Denniston, A. K. (2019). Deep learning for detecting retinal diseases in optical coherence tomography images. *Nature Medicine*, 25(8), 1342–1350.

McKinney, S. M., Sieniek, M., Godbole, V., Godwin, J., Antropova, N., Ashrafian, H., Back, T., Chesus, M., Corrado, G. C., Darzi, A., and Etemadi, M. (2020). International Evaluation of an AI System for Breast Cancer Screening. *Nature*, 577(7788), 89–94.

National Cancer Control Plan. (2018). National Strategic Plan for the Prevention and Control of Non-Communicable Diseases. *Federal Ministry of Health, Nigeria*.

Nigeria Cancer Health Statistics Report. (2021). *World Health Organization (WHO) Regional Office for Africa*.

Nigeria Population and Cancer Statistics. (2022). *International Agency for Research on Cancer (IARC)*, World Cancer Observatory.

Oche, M. O., and Okwundu, N. (2021). The emerging role of machine learning in cancer research in Sub-Saharan Africa. *West African Journal of Medicine*, 38(5), 422–429.

Onyeka, T. C., and Azubuike, M. C. (2019). Barriers to cancer diagnosis and treatment in Nigeria: A public health perspective. *Nigerian Medical Journal*, 60(2), 49–54.

Rajpurkar, P., Irvin, J., Ball, R. L., Zhu, K., Yang, B., Mehta, H., Duan, T., Ding, D., Bagul, A., Langlotz, C. P., and Shpanskaya, K. (2018). Deep Learning for Chest Radiograph Diagnosis: A Retrospective Comparison of the CheXNeXt Algorithm to Practicing Radiologists. *PLoS Medicine*, 15(11), e1002686.

Uche, N. O., and Adebayo, B. (2023). The role of artificial intelligence in advancing cancer care in Nigeria: A systematic review. *African Health Sciences*, 23(1), 1–8.

Wang, Z., Liu, L., and Zhang, C. (2021). Deep Learning-Based Prognostic Model for Breast Cancer: Predicting Disease-Free Survival and Overall Survival Using Histopathological and Clinical Data. *Nature Communications in Medicine*, 2(1), 1–10.